Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
- 26 March 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (7), 1252-1256
- https://doi.org/10.1038/leu.2009.53
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouseBlood, 2008
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood, 2007
- Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disordersBlood, 2007
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences of the United States of America, 2007
- Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformationNature Medicine, 2006
- Ribosomal Protein S24 Gene Is Mutated in Diamond-Blackfan AnemiaAmerican Journal of Human Genetics, 2006
- Impaired ribosome biogenesis in Diamond-Blackfan anemiaBlood, 2006
- Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunitsBlood, 2006
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences of the United States of America, 1971